Authors: Laihinen, A Ruottinen, H Rinne, JO Haaparanta, M Bergman, J Solin, O Koskenvuo, M Marttila, R Rinne, UK

Citation: A. Laihinen et al., Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [F-18]6-fluorodopa PET, J NEUROL, 247, 2000, pp. 110-113

Authors: Kemppainen, N Ruottinen, H Nagren, K Rinne, JO

Citation: N. Kemppainen et al., PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD, NEUROLOGY, 55(2), 2000, pp. 205-209

Authors: Rinne, JO Portin, R Ruottinen, H Nurmi, E Bergman, J Haaparanta, M Solin, O

Citation: Jo. Rinne et al., Cognitive impairment and the brain dopaminergic system in Parkinson disease - [F-18]fluorodopa positron emission tomographic study, ARCH NEUROL, 57(4), 2000, pp. 470-475

Authors: Rinne, JO Bergman, J Ruottinen, H Haaparanta, M Eronen, E Oikonen, V Sonninen, P Solin, O

Citation: Jo. Rinne et al., Striatal uptake of a novel PET ligand, [F-18]beta-CFT, is reduced in earlyParkinson's disease, SYNAPSE, 31(2), 1999, pp. 119-124

Authors: Rinne, JO Ruottinen, H Bergman, J Haaparanta, M Sonninen, P Solin, O

Citation: Jo. Rinne et al., Usefulness of a dopamine transporter PET ligand [F-18]beta-CFT in assessing disability in Parkinson's disease, J NE NE PSY, 67(6), 1999, pp. 737-741